Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$14.65 USD
-0.50 (-3.30%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.63 -0.02 (-0.14%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Castle Biosciences, Inc. has a market cap of $437.42M, which represents its share price of $15.15 multiplied by its outstanding shares number of 28.87M. As a small-cap company, CSTL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CSTL 14.65 -0.50(-3.30%)
Will CSTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSTL
New Strong Sell Stocks for August 1st
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
GSK (GSK) Q1 Earnings Surpass Estimates
Other News for CSTL
Examining the Future: Castle Biosciences's Earnings Outlook
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference | CSTL ...
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the ...
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses
Castle Biosciences (CSTL) Gains FDA Breakthrough Device Status for Melanoma Test | CSTL Stock News